Is MiMedx Group, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for MiMedx Group, Inc. has moved from attractive to fair. The company appears to be fairly valued given its current P/E ratio of 24, which is lower than the peer average P/E of approximately 33.09, and an EV to EBITDA ratio of 14.64, which is also below the peer average of 18.90. Additionally, the company boasts a strong ROCE of 47.22% and ROE of 19.84%, indicating effective capital utilization and profitability.
In comparison to its peers, LeMaitre Vascular, Inc. has a higher P/E of 49.77 and an EV to EBITDA of 33.90, while Stevanato Group SpA is valued attractively with a P/E of 51.03. Despite MiMedx's fair valuation, it has shown strong performance over the past three years with a return of 158.45%, significantly outpacing the S&P 500's return of 76.66% in the same period. However, its year-to-date return of -20.48% trails the S&P 500's 16.30%, suggesting some recent challenges.